The estimated Net Worth of James H Brauker is at least $6.74 Milione dollars as of 1 February 2006. James Brauker owns over 14,375 units of Dexcom Inc stock worth over $6,740,872 and over the last 19 years James sold DXCM stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Brauker DXCM stock SEC Form 4 insiders trading
James has made over 1 trades of the Dexcom Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently James exercised 14,375 units of DXCM stock worth $4,313 on 1 February 2006.
The largest trade James's ever made was exercising 14,375 units of Dexcom Inc stock on 1 February 2006 worth over $4,313. On average, James trades about 2,875 units every 0 days since 2005. As of 1 February 2006 James still owns at least 98,450 units of Dexcom Inc stock.
You can see the complete history of James Brauker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Brauker's mailing address?
James's mailing address filed with the SEC is 5555 OBERLIN DRIVE, , SAN DIEGO, CA, 92121.
Insiders trading at Dexcom Inc
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff e Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
What does Dexcom Inc do?
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
What does Dexcom Inc's logo look like?
Complete history of James Brauker stock trades at Dexcom Inc
Dexcom Inc executives and stock owners
Dexcom Inc executives and other stock owners filed with the SEC include:
-
Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer -
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer -
Richard Doubleday,
Executive Vice President, Chief Commercial Officer -
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development -
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development -
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs -
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres -
Jacob Steven Leach,
Exec. VP & CTO -
Bridgette Heller,
Independent Director -
Mark Foletta,
Lead Independent Director -
Eric Topol,
Independent Director -
Jay Skyler,
Independent Director -
Nicholas Augustinos,
Independent Director -
Steven Altman,
Independent Director -
Barbara Kahn,
Independent Director -
Richard Collins,
Independent Director -
Kyle Malady,
Independent Director -
Karen Dahut,
Independent Director -
Shelly Selvaraj,
Senior Vice President - Information Technology -
Jeffrey Moy,
Senior Vice President - Operations -
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer -
Patrick Murphy,
Executive Vice President, Chief Legal Officer -
Jake Leach,
Executive Vice President, Chief Technology Officer -
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology -
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs -
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures -
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. -
Sadie M. Stern,
Exec. VP & Chief HR Officer -
Chad M. Patterson,
Exec. VP of Global Marketing -
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations -
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer -
John Lister,
VP, Legal Affairs -
Terrance H Gregg,
Director -
Jess Roper,
VP, CFO -
Jorge A Valdes,
Vice President of Engineering -
Girish Naganathan,
EVP Chief Technology Officer -
Heather S Ace,
SVP Human Resources -
Kevin M Sun,
VP, Corp Controller & Treasury -
Jonathan T Md Lord,
Director -
Glen D Nelson,
Director -
Peter Gerhardsson,
VP, Int'l Business Development -
David Carner,
VP, Quality Assurance -
Laura Johnson,
V.P., Intellectual Property -
Martin Doordan,
Director -
Sean Carney,
Director -
John Riolo,
VP of Quality Assurance -
Claudia Graham,
VP, Marketing -
Donald A Lucas,
Director -
Donald L Lucas,
Director -
Mark Brister,
VP, Advanced Development Teams -
Richard Yang,
V.P., Strategic Affairs -
James H Brauker,
VP, Research & Development -
Rodney L Kellogg,
Vice President of Sales -
Andrew P Rasdal,
President and CEO -
Steven J Kemper,
Chief Financial Officer -
Kim D Blickenstaff,
Director -
Tae Andrews,
Vice President of Marketing -
Paul Travelers Companies In...,
-
Pincus Private Equity Viii ...,
-
Brenton Karl Ahrens,
Director -
Nancy Sfog City Management ...,
-
Equity Partners Ii Llccanaa...,
-
Paul Travelers Companies In...,
-
Eric A Charmers Landing Llc...,
-
Scott Lwindamere Llcwindame...,
-
Equity Partners Ii Llc Waub...,
-
Teri L Lawver,
EVP Chief Commercial Officer -
Paul R Flynn,
EVP Global Revenue -
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev -
Sumi Shrishrimal,
SVP Chief Risk Officer -
Chad Patterson,
EVP Global Marketing -
Barry J. Regan,
EVP Operations -
Jacob Steven Leach,
EVP, Chief Operating Officer -
Rimma Driscoll,
Director -
Michael Jon Brown,
EVP, Chief Legal Officer -
Sadie Stern,
EVP, Chief HR Officer